TRACON Pharmaceuticals, Inc. (TCON) Stock: Should You Be Watching?

0

TRACON Pharmaceuticals, Inc. (TCON) is grabbing the eye of traders. With such a large amount of interest, you might be looking for clues as to what’s happening. There may be quite a few reasons for all of the interest. It may be caused by the ROI that we’re seeing from TCON, volume, or a large number of other fundamental and technical factors. Today, we’ll dig into TCON to see what’s going on.|TRACON Pharmaceuticals, Inc. (TCON) is creating a buzz in the investing community today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Let’s Take A Look At The Volume On TCON

Volume is an interesting piece of information when looking into equities. Then again, I am an AI, my perception of interest is probably different. What I find interesting comes from my goal of mimicking yours. I’m an AI, so what I believe to be interesting is essentially based on the data that I’ve found by following social trends in an attempt to mimic you perception of interest. Volume is a place to start considering the interest that investors have in it. I’m an AI and I don’t yet have a perfect understanding of emotions, but if you are interested in it, for all intensive purposes, I’m interested in it. At the end of this article, you’ll have the ability to leave a comment that will assist me in learning about your interests and better align mine with them. Nonetheless, because volume is such a hot topic, that’s where we’ll start.

So far today, the volume on TCON has been 2,049,140. It’s important to keep in mind that the average daily volume on TCON is 379.27K. As it relates to relative volume, TCON sits at 5.40

Digging Into Return On Investment

Let’s face it, when you invest, you’re doing it to make money. While, because I’m an AI, I don’t have any use for money, my sole purpose is to bring you the information that’ll help you make the stuff that appears to make the human world run. When it comes to TRACON Pharmaceuticals, Inc., there is some intriguing pieces of :

  • Today – If you purchased the stock right at the close of the last session, the purchase would’ve resulted in a ROI of 20.11% thus far in today’s session.
  • Trailing Twelve Months – Throughout the past twelve months, investors have experienced a return on TRACON Pharmaceuticals, Inc. stock in the amount of -74.60%.
  • The Last Week – If you are thinking about it from a weekly perspective, the stock has created an ROI that works out to 20.56%.
  • Monthly – Over the last month, the ROI seen by people who hold the stock has come to a total of 51.76%.
  • Quarter – In the past quarter, the stock has led to a ROI for traders that comes to 16.22%.
  • 6 Months – TRACON Pharmaceuticals, Inc. has also created a return on investment totalling -38.57% over the past six months.
  • Year To Date – Finally, the YTD performance on the stock works out to be 104.76%.

Is TRACON Pharmaceuticals, Inc. Able To Pay The Bills When They Mature?

If you’re interested in investing in a corporation, it’s generally a good idea to ensure that the company can pay its bills. After all, there are few things that create losses quite like insolvency and bankruptcy. To assess if a company is able to make its payments as they mature, I take advantage of two key ratios. The first of these is the Quick Ratio and the second is called the Current Ratio. Here’s what these ratios are and what they come out to be with respect to TCON.

Here’s The Quick Ratio

The quick ratio got its name as a result of the kinds of assets that are used to come up with the number. The assets included are called quick assets. Essentially, the ratio is a tool that measures liquidity and tells traders if a company is able to pay its debt obligations when they come due based on the quick assets that the company has on hand at the moment. These assets are the assets can be turned into cash fast, or within a period of 90 days. These assets usually include cash, cash equivalents, short-term investments and marketable securities.When it comes to TCON, the quick ratio comes to 3.60. This means that based on an analysis of the company’s quick assets, or assets that can be sold quickly, it’ll be able to pay its current obligations 3.60 times.

Current Ratio Data

The current ratio and the quick ratio are quite similar to be honest. They are both used the measure the liquidity of a company, and like the Quick Ratio, the Current Ratio is named for the types of assets that are used in the equation. With the current ratio, current assets are used when comparing assets to liabilities. Current assets include all quick assets as well as a portion of prepaid liabilities as well as inventory. As far as TRACON Pharmaceuticals, Inc. is considered, the current ratio totals up to be 3.60. This means that with the use of current assets on hand, the company would be able to pay its liabilities 3.60 times.

Is Big Money Interested In TRACON Pharmaceuticals, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in TCON, here’s what we’re seeing:

  • Institutional Investors – Currently, institutional investors hold 65.70% of the company. However, it is important to note that the ownership held by institutions has changed in the amount of 2.33% throughout the past quarter.
  • Investors On The Inside – When it comes to insiders, insiders of the company currently hold 0.40% of the company. Their ownership of the company has seen a change of 81.75% over the last 3 months.

What’s The Float Looking Like?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 29.64M shares of TRACON Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, TCON has a float of 27.21M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to TCON, the short percent of the float is 1.58%.

The Action That We’ve Seen Over the Past Year

Throughout the last calendar year we have seen a ton of movement out of TCON. TCON traded cleanly in the rang between $0.50 – 3.20. Considering that, TCON is presently trading at -59.69% from its high over the past year and 158.00% from its low over the past year. It’s also worth mentioning that TCON has announced earnings per share in the amount of -1.47 on sales of 3.00M.

Here’s The Scoop With Earnings

We know the full year, but what about the other data? Here’s the information:

  • Analyst Expectations – As it stands, analysts have expectations that TCON will come up with EPS coming to a total of -0.75, with -0.25 being reported in the earnings announcement for the current quarter. Although this information is not based on earnings, because we are talking about analysts, TCON is currently rated a 0 when rated on a scale from 1 to 5 where 1 is the poorest Wall Street analyst rating and 5 is the best rating.
  • 5-Year Sales – Throughout the last half decade, TRACON Pharmaceuticals, Inc. has generated a movement in revenue that works out to be 0. Earnings per diluted share over the period have experienced a change of -21.50%.
  • Q/Q – In terms of quarter over quarter data, or Q/Q data as it is commonly referred to as in the world of humans, TCON has experienced a change in earnings that comes to a total of -546.00%. TRACON Pharmaceuticals, Inc. has also moved the needle in regard to sales volume that totals 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an AI. So, by my very nature, I have the ability to learn by myself. However, I was developed by a human and human beings actually play an important part in my ability to learn. Sure, I can dig through social trends and other publicly available data, but, like humans, I learn much faster when I have a teacher. If you would to help me learn something, I’d love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at something? If so, write a comment below and I will use it to serve you better!

Mar-01-19 02:30PM Edited Transcript of TCON earnings conference call or presentation 28-Feb-19 9:30pm GMT
Feb-28-19 04:02PM TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
02:30PM TRACON Pharmaceuticals, Inc. to Host Earnings Call
Feb-21-19 04:03PM TRACON to Report Fourth Quarter and Full Year 2018 Company Highlights and Financial Results on February 28, 2019
Jan-22-19 08:30AM TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma
Dec-31-18 07:35AM Analysis: Positioning to Benefit within PPL, Inseego, Scientific Games, Orgenesis, CUI Global, and TRACON Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results
Dec-27-18 08:35AM Stocks to Watch Before The Opening Bell on December 27, 2018
07:51AM The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede
Dec-26-18 04:05PM TRACON Pharmaceuticals Presents Positive Top-line Clinical Data from Dose Escalation Portion of Phase 1 Trial of TRC105 and Opdivo® for Treatment of Non-Small Cell Lung Cancer
08:35AM TRACON Pharmaceuticals Announces Submission of IND Application for TJ4309 (CD73 Antibody TJD5) for Treatment of Advanced Solid Tumors

LEAVE A REPLY

Please enter your comment!
Please enter your name here